KLOR-Con/EF
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- KLOR-Con/EF
- Generic name
- POTASSIUM BICARBONATE
- Manufacturer
- Upsher-Smith Laboratories, Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- f9d85c4f-aa46-40b2-ad76-89dbf6ec8e4d
- SPL ID
- 39e79ec3-bfd0-e47d-e063-6294a90a25d4
- Version
- 5
- Effective date
- 2025-07-14
- Source export date
- 2026-09-28
- Source partition
- 12
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/663999d0fe1757c1e2cd13a4799d76d875f663e0bc57701092264ebe7febfc18/drug-label-0012-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 06:29:32
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| brand name | KLOR-Con/EF | openfda.brand_name | |
| generic name | POTASSIUM BICARBONATE | openfda.generic_name | |
| manufacturer name | Upsher-Smith Laboratories, Inc. | openfda.manufacturer_name | |
| ndc | package | 0245-5326-30 | openfda.package_ndc |
| ndc | package | 0245-5326-01 | openfda.package_ndc |
| ndc | package | 0245-5326-89 | openfda.package_ndc |
| ndc | product | 0245-5326 | openfda.product_ndc |
| ndc11 | package | 00245532689 | derived:openfda.package_ndc |
| ndc11 | package | 00245532601 | derived:openfda.package_ndc |
| ndc11 | package | 00245532630 | derived:openfda.package_ndc |
| rxcui | 1537082 | openfda.rxcui | |
| rxcui | 1088772 | openfda.rxcui | |
| spl id | 39e79ec3-bfd0-e47d-e063-6294a90a25d4 | id | |
| spl set id | f9d85c4f-aa46-40b2-ad76-89dbf6ec8e4d | set_id | |
| unii | HM5Z15LEBN | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS Hyperkalemia [see OVERDOSAGE ] In patients with impaired mechanisms for excreting potassium, the administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment. Interaction with Potassium-Sparing Diuretics Hypokalemia should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (e.g., spironolactone, triamterene or amiloride), since the simultaneous administration of these agents can produce severe hyperkalemia. Interaction with Angiotensin Converting Enzyme Inhibitors Angiotensin converting enzyme (ACE) inhibitors (e.g., captopril, enalapril) will produce some potassium retention by inhibiting aldosterone production. Potassium supplements should be given to patients receiving ACE inhibitors only with close monitoring. Metabolic Acidosis Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt such as potassium bicarbonate, potassium citrate, potassium acetate or potassium gluconate.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS One of the most severe adverse effects is hyperkalemia [see CONTRAINDICATIONS , WARNINGS and OVERDOSAGE ] . The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals or reducing the dose.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.